PCVX Share Price Performance
US$40.74
-71.13 (-63.58%)
Price US$40.74
Share PriceUS$40.74
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Jul 07
Vaxcyte, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
PCVX Community Narratives
There are no narratives available yet.
Vaxcyte, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.22
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Vaxcyte, Inc. Competitors
Snowflake Analysis
About PCVX
- Founded
- 2013
- Employees
- 414
- CEO
- WebsiteView website
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.8%
- 3 Months: 8.3%
- 1 Year: 17.8%
- Year to Date: 15.4%
Over the last 7 days, the market has remained flat, although notably the Utilities sector gained 3.1% in that time. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›